Balanced news tone
News Sentiment
VYGR sentiment intelligence
Voyager Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
60 relevant articles
Price is moving more forcefully than the current news tone suggests.
79/100 classification confidence.
directly relevant articles
high-authority source matches
-9.0% over one week, -1.7% over four weeks, trend inactive, and below fair value.
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
79/100 classification
One-week reaction
-9.0%
Price reacting lower
Trend fit
Trend inactive
-1.7% over four weeks
Fair value
-40.6%
Below fair value
Value support
Sentiment Mix
Positive, neutral, negative
Positive
18
Neutral
35
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Moomoo
Direct company coverage
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8
Wedbush has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained its target price at $8. This indicates the firm's continued confidence in the company's financial performance or future prospects.
- Tone
- Positive 77/100
- Event
- Analyst action
- Published
- 15 Jul 2026 00:20
- Source
- Moomoo
Moomoo
Direct company coverage
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12
CCORF has reiterated its Buy rating for Voyager Therapeutics (VYGR.US) and maintained a target price of $12. This indicates a continued positive outlook on the company's stock performance from the analyst.
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 14 Jul 2026 16:12
- Source
- Moomoo
Simply Wall Street
Direct company coverage
Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early
Voyager Therapeutics' stock has recently dropped 10%, yet insiders who sold US$405k worth of stock over the past year might have sold too early, as their average selling price of US$3.79 is still below the current share price of US$3.24. Although insider selling occurred at a pri
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 14 Jul 2026 11:28
- Source
- Simply Wall Street
GlobeNewswire
Direct company coverage
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
Voyager Therapeutics announced positive six-month GLP toxicology data for its investigational gene therapy VY1706, showing it was well-tolerated and reduced tau protein by up to 75% in non-human primates after a single intravenous dose. The company received FDA IND clearance for
- Tone
- Positive 74/100
- Event
- Regulatory and legal
- Published
- 14 Jul 2026 00:20
- Source
- GlobeNewswire
grafa.com
Direct company coverage
Voyager reports VY1706 Alzheimer’s therapy data
Voyager Therapeutics reported positive six-month toxicology results for its investigational Alzheimer’s gene therapy, VY1706, showing significant reductions in tau protein levels in non-human primates. The therapy was well-tolerated, and the FDA has cleared Voyager's IND applicat
- Tone
- Positive 71/100
- Event
- Regulatory and legal
- Published
- 13 Jul 2026 17:41
- Source
- grafa.com
Investing.com
Direct company coverage
Voyager presents six-month data for Alzheimer’s gene therapy
Voyager Therapeutics Inc. presented positive six-month toxicology data for its investigational gene therapy VY1706 for Alzheimer's disease at a conference in London. The data showed that VY1706 significantly reduced tau protein in non-human primates and was well tolerated. The co
- Tone
- Positive 72/100
- Event
- Regulatory and legal
- Published
- 13 Jul 2026 16:41
- Source
- Investing.com
GuruFocus
Direct company coverage
Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 13:05
- Source
- GuruFocus
Stock Titan
Direct company coverage
[8-K] Voyager Therapeutics, Inc. Reports Material Event
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 12:44
- Source
- Stock Titan
MT Newswires
Direct company coverage
Voyager Therapeutics Expects to Start Early Alzheimer's Study in Adults in H2
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 13 Jul 2026 12:35
- Source
- MT Newswires
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Stock Titan
Direct company coverage
Single-dose Alzheimer’s gene therapy from Voyager lowers brain tau in primates
Voyager Therapeutics reported positive 6-month GLP toxicology results for its investigational Alzheimer’s gene therapy, VY1706. The single intravenous dose was well tolerated in non-human primates and significantly reduced tau protein by up to 75% in key brain regions. The compan
- Tone
- Positive 72/100
- Event
- Regulatory and legal
- Published
- 13 Jul 2026 11:41
- Source
- Stock Titan
MarketBeat
Direct company coverage
Voyager Therapeutics (VYGR) Short Interest & Short Float | Updated Jul 2026
As of June 30, 2026, Voyager Therapeutics (VYGR) had a short interest of 3.57 million shares, which is 6.78% of its public float, marking a 1.99% decrease from the previous report. The short interest ratio is 5.1 days to cover. The article provides detailed historical short inter
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jul 2026 23:41
- Source
- MarketBeat
AD HOC NEWS
Direct company coverage
Voyager Therapeutics outlines gene therapy pipeline. Clinical partnerships frame the next phase
Voyager Therapeutics, a clinical-stage biotechnology company, is focused on developing gene therapies for serious neurological diseases, particularly targeting conditions of the central nervous system using AAV-based therapies. The company employs a business model that combines i
- Tone
- Positive 68/100
- Event
- Market update
- Published
- 08 Jul 2026 15:02
- Source
- AD HOC NEWS
AD HOC NEWS
Direct company coverage
Voyager Therapeutics outlines its gene therapy pipeline. Investors focus on neurology targets
Voyager Therapeutics is advancing a neurology-focused gene therapy pipeline, utilizing its CNS delivery technology to develop treatments for severe neurological conditions. The company's strategy involves both internal development and collaborations with larger pharmaceutical par
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 07 Jul 2026 21:39
- Source
- AD HOC NEWS
Finviz
Direct company coverage
VYGR - Voyager Therapeutics Inc Latest SEC Filings
This article provides the latest SEC filings and comprehensive financial data for Voyager Therapeutics Inc (VYGR). It includes detailed financial metrics such as market capitalization, income, sales, P/E ratios, employee count, and stock performance data. The report also highligh
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 09:10
- Source
- Finviz
24/7 Wall St.
Direct company coverage
Voyager Therapeutics : VYGR
This article provides an overview of Voyager Therapeutics Inc (VYGR), a biotechnology firm specializing in gene therapies for neurological diseases like Alzheimer's. It highlights the company's leading project, VY-TAU01, and its collaborations with partners such as Alexion and No
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 02 Jul 2026 22:11
- Source
- 24/7 Wall St.
TradingView
Direct company coverage
Enterprise value to revenue forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
This article provides the enterprise value to revenue forward for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It confirms that the financial data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The content appears to be a financial data point from Trad
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 01 Jul 2026 09:41
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Voyager Therapeutics, Inc. – FWB:VT6
This article provides the "Price to book forward" financial metric for Voyager Therapeutics, Inc., traded on the Frankfurt Stock Exchange under the ticker FWB:VT6. It indicates that the period value and changes are available, sourced from FactSet Research Systems Inc. and ICE Dat
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 19:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
The article focuses on the "Price to sales forward" metric for Voyager Therapeutics, Inc. (NASDAQ: VYGR). It serves as a brief financial data point for the company, indicating a specific period, value, and change percentage for this metric. The content itself seems to be a snapsh
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 19:39
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Voyager Therapeutics, Inc. – FWB:VT6
This article displays the "Price to sales forward" metric for Voyager Therapeutics, Inc. (FWB:VT6). It includes a table showing the period, value, change, and percentage change for this financial metric. The content itself provides financial data within the TradingView platform.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 12:10
- Source
- TradingView
Stock Titan
Direct company coverage
Voyager’s Alzheimer’s gene therapy gets a late-breaking AAIC poster
Voyager Therapeutics will present a late-breaking poster on its investigational gene therapy, VY1706, for Alzheimer's disease at the Alzheimer's Association International Conference (AAIC) in London, July 12–15, 2026. This announcement follows the recent FDA IND clearance for VY1
- Tone
- Positive 66/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 09:40
- Source
- Stock Titan
Market source
Direct company coverage
Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 30 Jun 2026 07:00
- Source
- Market source
TradingView
Direct company coverage
Price to earnings forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
This page provides financial information for Voyager Therapeutics, Inc. (NASDAQ: VYGR), specifically focusing on its forward price-to-earnings ratio. The content is primarily a data placeholder from TradingView, indicating where detailed financial metrics for the company would be
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 30 Jun 2026 04:09
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Voyager Therapeutics, Inc. – FWB:VT6
This article provides financial information for Voyager Therapeutics, Inc. (FWB:VT6), specifically focusing on its enterprise value to EBIT forward. The content appears to be a direct data point from a financial platform like TradingView, indicating a value for this metric during
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Jun 2026 04:09
- Source
- TradingView
GlobeNewswire
Direct company coverage
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 12:01
- Source
- GlobeNewswire
Investing.com Australia
Direct company coverage
Voyager to present Alzheimer’s gene therapy data at AAIC By Investing.com
Voyager Therapeutics Inc. (NASDAQ:VYGR) is set to present preclinical data for its Alzheimer’s gene therapy, VY1706, at the Alzheimer’s Association International Conference. The company recently received FDA clearance for its Investigational New Drug application and plans to star
- Tone
- Positive 74/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 12:41
- Source
- Investing.com Australia
GlobeNewswire
Direct company coverage
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s
Voyager Therapeutics announced that its investigational gene therapy, VY1706, for Alzheimer's disease will be featured in a late-breaking poster presentation at the upcoming Alzheimer's Association International Conference (AAIC) in London. The company recently received FDA Inves
- Tone
- Positive 74/100
- Event
- Regulatory and legal
- Published
- 29 Jun 2026 12:09
- Source
- GlobeNewswire
TradingView
Direct company coverage
Price to book forward of Voyager Therapeutics, Inc. – NASDAQ:VYGR
This page provides financial information for Voyager Therapeutics, Inc. (NASDAQ:VYGR), specifically focusing on its price-to-book forward ratio. The content is presented within the TradingView platform, offering various financial tools and market data services.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 23:39
- Source
- TradingView
Investing.com
Direct company coverage
Voyager to present Alzheimer’s gene therapy data at AAIC
Voyager Therapeutics (NASDAQ:VYGR) will present preclinical data for its Alzheimer's disease gene therapy, VY1706, at the Alzheimer's Association International Conference. The company recently received FDA clearance for its Investigational New Drug application for VY1706, which i
- Tone
- Positive 71/100
- Event
- Regulatory and legal
- Published
- 28 Jun 2026 11:10
- Source
- Investing.com
TradingView
Direct company coverage
VYGR Forecast — Price Target — Prediction for 2027
This article provides a forecast for Voyager Therapeutics, Inc. (VYGR) stock, including analyst price targets and ratings. It details the stock's current price, historical performance, financial metrics like earnings and revenue, and upcoming earnings dates. The forecast section
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 27 Jun 2026 13:10
- Source
- TradingView